# Neena Kadaba

> Neena Kadaba is a Series B investor at Quark Venture backing Therapeutics and Biotechnology. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Quark Venture](https://shizune.co/investors/profile/quark-venture)
- Location: Berkeley, United States
- Total investments: 1
- Last investment: Jan 2020
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/neena-kadaba-964aaa2/

Neena Kadaba is a Series B investor at Quark Venture in Berkeley focused on Therapeutics and Biotechnology. Neena Kadaba works to initiate new collaborations between industry and QB3 campus scientists and manages QB3’s multi-year, multimillion dollar alliance with Pfizer. She runs the Quadrant industry speakers seminar series to link scientists from industry to scientists in academia and startups, writes the quadrant@qb3 newsletter focused onhighlighting innovation at the QB3 campuses, and manages QB3’s internship program. Previously, she co-founded Cypress Innovations and was an associate and Kauffman Fellow in the venture capital group at Itochu Technology. She earned her BS at the Massachusetts Institute of Technology and her PhD in chemistry at the California Institute of Technology.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 1 | 100% |
| Biotechnology | 1 | 100% |
| Medical Device | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Eyevensys | Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures. | $30M | Series B | Jan 08, 2020 |  |

1 of 1 investments shown.

## Co-investors
- [Boehringer Ingelheim Venture Fund](https://shizune.co/investors/profile/boehringer-ingelheim-venture-fund) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Global health sciences venture fund](https://shizune.co/investors/profile/global-health-sciences-venture-fund) — VC Fund, 1 deal together
- [Inserm Transfert Initiative](https://shizune.co/investors/profile/inserm-transfert-initiative) — VC Fund, 1 deal together
- [Karista](https://shizune.co/investors/profile/karista) — VC Fund, 1 deal together
- [Pontifax](https://shizune.co/investors/profile/pontifax) — VC Fund, 1 deal together

## About Quark Venture

VC Fund · Vancouver, Canada

Established in 2015, Quark Venture Inc. is a venture capital investment firm, headquartered in Vancouver, Canada, and is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.

4 contacts available at Quark Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Karimah Es Sabar | Chief Executive Officer & Partner | https://shizune.co/investors/profile/karimah-es-sabar |
| Neena Kadaba | Director, Science | https://shizune.co/investors/profile/neena-kadaba |
| Zafrira Avnur | Chief Scientific Officer | https://shizune.co/investors/profile/zafrira-avnur |
| Jesson Chen | Co-Founder, Chairman & Partner | https://shizune.co/investors/profile/jesson-chen |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Neena Kadaba invest in?

Neena Kadaba invests primarily in Therapeutics, Biotechnology and Medical Device startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Neena Kadaba last invest?

The most recent investment recorded for Neena Kadaba closed in Jan 2020. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co